Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Feb 11:11:169-184.
doi: 10.2147/CLEP.S188752. eCollection 2019.

Randomized clinical trials with run-in periods: frequency, characteristics and reporting

David Ruben Teindl Laursen  1   2   3   4 , Asger Sand Paludan-Müller  2 , Asbjørn Hróbjartsson  1   3   4
Affiliations

Randomized clinical trials with run-in periods: frequency, characteristics and reporting

David Ruben Teindl Laursen et al. Clin Epidemiol. .

Abstract

Background: Run-in periods are occasionally used in randomized clinical trials to exclude patients after inclusion, but before randomization. In theory, run-in periods increase the probability of detecting a potential treatment effect, at the cost of possibly affecting external and internal validity. Adequate reporting of exclusions during the run-in period is a prerequisite for judging the risk of compromised validity. Our study aims were to assess the proportion of randomized clinical trials with run-in periods, to characterize such trials and the types of run-in periods and to assess their reporting.

Materials and methods: This was an observational study of 470 PubMed-indexed randomized controlled trial publications from 2014. We compared trials with and without run-in periods, described the types of run-in periods and evaluated the completeness of their reporting by noting whether publications stated the number of excluded patients, reasons for exclusion and baseline characteristics of the excluded patients.

Results: Twenty-five trials reported a run-in period (5%). These were larger than other trials (median number of randomized patients 217 vs 90, P=0.01) and more commonly industry trials (11% vs 3%, P<0.01). The run-in procedures varied in design and purpose. In 23 out of 25 trials (88%), the run-in period was incompletely reported, mostly due to missing baseline characteristics.

Conclusion: Approximately 1 in 20 trials used run-in periods, though much more frequently in industry trials. Reporting of the run-in period was often incomplete, precluding a meaningful assessment of the impact of the run-in period on the validity of trial results. We suggest that current trials with run-in periods are interpreted with caution and that updates of reporting guidelines for randomized trials address the issue.

Keywords: enrichment design; lead-in periods; research methodology; run-in periods; single-blind placebo; washout periods.

PubMed Disclaimer

Conflict of interest statement

Disclosure The authors report no conflicts of interest in this work.

Figures

Figure 1
Figure 1
Flowchart of screening for randomized clinical trials and for run-in periods.a Notes: aWe screened PubMed publications from 2014 one by one in random order until we had obtained 25 randomized clinical trials reporting a run-in period. The PubMed query used was: “(randomized controlled trial[Publication Type]) AND (“2014/01/01”[Date - Publication]: “2014/12/31”[Date - Publication])”.
See this image and copyright information in PMC

References

    1. Pablos-Méndez A, Barr RG, Shea S. Run-in periods in randomized trials: implications for the application of results in clinical practice. JAMA. 1998;279(3):222–225. - PubMed
    1. Talley NJ, Janssens J, Lauritsen K, Rácz I, Bolling-Sternevald E. Eradication of Helicobacter pylori in functional dyspepsia: randomised double blind placebo controlled trial with 12 months’ follow up. BMJ. 1999;318(7187):833–837. - PMC - PubMed
    1. Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER), Center for Devices and Radiological Health (CDRH) Draft guidance for industry: enrichment strategies for clinical trials to support approval of human drugs and biological products. [Accessed April 9, 2017]. Available from: http://www.fda.gov/downloads/drugs/guid-ancecomplianceregulatoryinformat.... Published December 2012.
    1. Hale M, Khan A, Kutch M, Li S. Once-daily OROS hydromorphone ER compared with placebo in opioid-tolerant patients with chronic low back pain. Curr Med Res Opin. 2010;26(6):1505–1518. - PubMed
    1. Lang JM, Buring JE, Rosner B, Cook N, Hennekens CH. Estimating the effect of the run-in on the power of the physicians’ health study. Stat Med. 1991;10(10):1585–1593. - PubMed